PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17825525-5	2007	DFMO increased EGFR phosphorylation on tyrosine residues 1173 (pY1173) and 845 (pY845) within 5 min.	Eflornithine	0-4	epidermal growth factor receptor	Homo sapiens	15-19	
17825525-10	2007	In addition, inhibition of integrin beta3 activity (with RGDS), Src activity (with PP2), or EGFR kinase activity (with AG1478), increased basal apoptosis and prevented protection conferred by either DFMO or EGF.	Eflornithine	199-203	epidermal growth factor receptor	Homo sapiens	92-96	
11688517-0	2001	Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture.	Eflornithine	10-40	epidermal growth factor receptor	Homo sapiens	79-111	
11688517-6	2001	Our results also indicated that the increase in EGFR induced by DFMO was not a non-specific consequence of inhibition of cell proliferation.	Eflornithine	64-68	epidermal growth factor receptor	Homo sapiens	48-52	
11688517-8	2001	We propose that physiologic levels of ODC activity may be critical for regulation of a yet undefined signalling pathway, whose blockade by DFMO leads to a compensatory increase in functional EGFR.	Eflornithine	139-143	epidermal growth factor receptor	Homo sapiens	191-195	
9626454-0	1998	Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.	Eflornithine	111-140	epidermal growth factor receptor	Homo sapiens	0-32	
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	238-267	epidermal growth factor receptor	Homo sapiens	55-87	
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	238-267	epidermal growth factor receptor	Homo sapiens	89-93	
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	269-273	epidermal growth factor receptor	Homo sapiens	55-87	
9626454-2	1998	The purpose of this study was to examine expression of epidermal growth factor receptor (EGFR) as a marker for progression of cervical intraepithelial neoplasia (CIN) and as a surrogate end point biomarker in a chemoprevention trial with alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase.	Eflornithine	269-273	epidermal growth factor receptor	Homo sapiens	89-93	
9626454-8	1998	Although the overall levels of EGFR expression were not modulated in either histological responders or nonresponders, responders showed a prominent down-regulation of EGFR expression away from the basal layer after DFMO treatment.	Eflornithine	215-219	epidermal growth factor receptor	Homo sapiens	167-171	
9626454-9	1998	Interestingly, pretreatment EGFR expression levels predicted for DFMO response [i.e., eight responses (72.7%) for 11 cases with RSI levels below 0.35 versus one response (9.1%) for 11 cases with RSI levels above 0.35 (P < 0.01)].	Eflornithine	65-69	epidermal growth factor receptor	Homo sapiens	28-32	
9626454-10	1998	These results suggest that CIN progression is associated with a spatial dysregulation of EGFR expression that can be reversed by DFMO treatment, especially in patients whose pretreatment CIN 3 lesions exhibit relatively low EGFR expression.	Eflornithine	129-133	epidermal growth factor receptor	Homo sapiens	89-93	
9626454-10	1998	These results suggest that CIN progression is associated with a spatial dysregulation of EGFR expression that can be reversed by DFMO treatment, especially in patients whose pretreatment CIN 3 lesions exhibit relatively low EGFR expression.	Eflornithine	129-133	epidermal growth factor receptor	Homo sapiens	224-228